A Dose Escalation Study of a Combination Antihypertensive Drug in the Treatment of Various Groups of Patients Who do Not Respond to Single Drug Treatment of Their High Blood Pressure (BP CRUSH)
A Prospective, Open-Label, Titration Study to Evaluate the Efficacy and Safety Safety of AZOR in Multiple Subgroups of Hypertensive Subjects Who Are Non-Responders to Anti-Hypertensive Monotherapy
Sponsor: Daiichi Sankyo
Listed as NCT00791258, this PHASE4 trial focuses on Hypertension and remains completed. Sponsored by Daiichi Sankyo, it has been updated 10 times since 2008, reflecting substantial change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Mar 2024 — Jul 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Mar 2024 [monthly]
Completed PHASE4
▶ Show 5 earlier versions
-
Feb 2019 — Jan 2021 [monthly]
Completed PHASE4
-
Jun 2018 — Feb 2019 [monthly]
Completed PHASE4
-
Sep 2017 — Jun 2018 [monthly]
Completed PHASE4
-
Feb 2017 — Sep 2017 [monthly]
Completed PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE4
First recorded
Nov 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Daiichi Sankyo
- Integrium
For direct contact, visit the study record on ClinicalTrials.gov .